BEACON trial analysis provides insights into BRAF-V600E-mutated colorectal cancer
Patients with metastatic colorectal cancer harboring BRAF-V600E mutations have poor prognoses, highlighting a need to identify biomarkers that can optimize treatment. The recent BEACON trial showed that the combination of encorafenib (BRAF inhibitor) and cetuximab (anti-EGFR antibody), with or without binimetinib (MEK inhibitor), improved overall survival, objective response rates and progression-free survival in pretreated patients compared to those receiving cetuximab with chemotherapy. In a follow-up analysis, researchers led by Scott Kopetz, M.D., Ph.D., performed genomic and transcriptional profiling on tumor tissue...










